Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
LLY stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Eli Lilly and Company stock logo

Eli Lilly and Company

LLY·NYSE

Last updated as of 2026-02-26 06:45 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

LLY stock price change

On the last trading day, LLY stock closed at 1028.83 USD, with a price change of -1.28% for the day.
Trade stock perps

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

LLY key data

Previous close1028.83 USD
Market cap970.55B USD
Volume2.45M
P/E ratio45.54
Dividend yield (TTM)0.58%
Dividend amount1.50 USD
Last ex-dividend dateNov 14, 2025
Last payment dateDec 10, 2025
EPS diluted (TTM)22.59 USD
Net income (FY)20.64B USD
Revenue (FY)65.18B USD
Next report dateApr 30, 2026
EPS estimate7.210 USD
Revenue estimate17.44B USD USD
Shares float851.51M
Beta (1Y)0.48
Tokenized stocks

Have you heard of stock tokens?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Eli Lilly and Company overview

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Headquarters
Indianapolis
Website
lilly.com
Founded
1876
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-

LLY Pulse

Daily updates on LLY stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• LLY Stock Price 24h change: -1.55%. From 1,058.56 USD to 1,042.15 USD. The decline was primarily driven by investor concerns over an intensifying price war in the weight-loss market after rival Novo Nordisk announced significant price cuts for Wegovy and Ozempic starting in 2027.
• From a technical perspective, the stock is showing "short-term consolidation with medium-term caution": while trading above its 5-day and 20-day SMAs, it remains below the 50-day SMA ($1,053.04). The RSI is neutral at 55.01, but a bearish MACD crossover suggests downward momentum persists despite strong support near the $1,000 psychological level.
• Eli Lilly's Zepbound outperformed Novo Nordisk's experimental drug CagriSema in a head-to-head trial, achieving 25.5% weight loss versus 23%, reinforcing Lilly's competitive edge in the GLP-1 market.
• The FDA approved and Lilly launched the multi-dose Zepbound KwikPen, a monthly device intended to improve patient adherence and convenience while maintaining competitive self-pay pricing.
• Clinical trial updates showed Omvoh's long-term efficacy in Crohn's disease and positive combination data for Taltz and Zepbound in psoriasis patients, highlighting pipeline depth beyond obesity treatments.
• Novo Nordisk announced it will slash list prices for Wegovy and Ozempic to $675 per month starting January 2027, signaling a major strategic shift toward affordability and volume in the metabolic drug sector.
• The FDA accepted Teva Pharmaceutical's application for a once-monthly long-acting injectable of olanzapine for schizophrenia, potentially addressing a significant unmet need in adherence for neuropsychiatric care.
See more
about 19h ago
• LLY Stock Price 24h change: +4.86%. From 1,009.52 USD to 1,058.56 USD.
• Yesterday's surge was driven by positive clinical trial news as rival Novo Nordisk's new weight-loss drug, CagriSema, underperformed Lilly's tirzepatide (Zepbound/Mounjaro) in a head-to-head study. Additionally, Lilly announced the FDA approval of a new multi-dose KwikPen for Zepbound, enhancing patient convenience and reducing production complexity.
• From a technical perspective, the market presents a "Strong Bullish" outlook across multiple timeframes. LLY is currently trading above its 20-day (1,036.61), 50-day (1,032.86), and 200-day (920.90) moving averages, indicating a sustained upward trend. While the RSI (64.82) suggests momentum is strong, indicators like the Stochastic Oscillator show "overbought" conditions, signaling a potential minor consolidation near the 1,065 resistance level.
• Novo Nordisk's experimental drug CagriSema achieved 23% weight loss in a Phase 3 trial, failing to beat the 25.5% benchmark set by Eli Lilly's tirzepatide, solidifying Lilly's market leadership.
• Eli Lilly launched a single-injector KwikPen for Zepbound, allowing patients to hold a full month's supply in one device, significantly improving the user experience compared to single-dose vials.
• Deutsche Bank reiterated a "Buy" rating with a $1,200 target, citing strong 2026 revenue guidance of $80-$83 billion driven by the rapid global scale-up of its obesity franchise.
• The U.S. FDA accepted Teva Pharmaceuticals' application for a once-monthly long-acting injectable for schizophrenia, highlighting a broader industry shift toward long-acting subcutaneous delivery systems.
• A new EFPIA report revealed that pharmaceutical clinical trials contributed over £31 billion to the European economy in 2025, prompting calls for policy reforms to boost R&D investment across the sector.
See more
about 1D ago

LLY stock price forecast

According to technical indicators for LLY stock, the price is likely to fluctuate within the range of 1080.23–1305.62 USD over the next week. Market analysts predict that the price of LLY stock will likely fluctuate within the range of 868.35–1421.15 USD over the next months.

Based on 1-year price forecasts from 85 analysts, the highest estimate is 1533.79 USD, while the lowest estimate is 773.97 USD.

For more information, please see the LLY stock price forecast page.

Latest LLY stock news

US Morning News Call | Trump Raises Global Tariffs to 15% From 10% After Supreme Court Loss

moomoo-证劵2026-02-24 13:06:49

US Morning News Call | Trump Raises Global Tariffs to 15% From 10% After Supreme Court Loss

moomoo-证劵2026-02-24 13:06:49

Novo plans to lower the prices of Ozempic and Wegovy as competition heats up

101 finance2026-02-24 13:12:40

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Finviz2026-02-24 17:33:10

Aktis Oncology to Present at Upcoming March Investor Conferences

Finviz2026-02-24 21:09:41

Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect

Finviz2026-02-25 03:12:35

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

Finviz2026-02-25 03:30:49

Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027

Finviz2026-02-25 09:15:08

Healthcare Industry Poised for Growth in 2026: Key Insights for Investors

101 finance2026-02-25 12:27:55

Healthcare Industry Poised for Growth in 2026: Key Insights for Investors

101 finance2026-02-25 12:27:55

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Finviz2026-02-25 13:03:48

Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

Finviz2026-02-25 15:04:01

Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

Finviz2026-02-25 15:57:39

Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study

Finviz2026-02-25 16:13:23

RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds

Finviz2026-02-26 02:51:37

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Eli Lilly and Company?

LLY is currently priced at 1028.83 USD — its price has changed by -1.28% over the past 24 hours. You can track the stock price performance of Eli Lilly and Company more closely on the price chart at the top of this page.

What is the stock ticker of Eli Lilly and Company?

Depending on the exchange, the stock ticker may vary. For instance, on NYSE, Eli Lilly and Company is traded under the ticker LLY.

What is the stock forecast of LLY?

We've gathered analysts' opinions on Eli Lilly and Company's future price. According to their forecasts, LLY has a maximum estimate of 10288.30 USD and a minimum estimate of 2057.66 USD.

What is the market cap of Eli Lilly and Company?

Eli Lilly and Company has a market capitalization of 970.55B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock token prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Stock token perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially stock token perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NYSE/
LLY